MECP2 and Alzheimer disease: Our results support the notion that Lpc-EV treatment produces MeCP2- and Sirt1-dependent upregulation of Mmp-2, Mmp-9, and Nep (Fig. 5f–h), which in turn reduces Aβ42 accumulation and improves neuroinflammatory responses and other AD-like pathology.